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To the Editor: The report by Campbell-Thompson and col-
leagues [1], providing evidence that pancreatic weight is reduced
irrespective of duration in type 1 diabetic donors, presented im-
portant characteristics of the pancreas in type 1 diabetes. We
would like to offer two comments and introduce our own results.
First, the report by Campbell-Thompson et al [1] did not
address potential differences in pancreatic weight in terms of
subtypes of type 1 diabetes. Two clinical subtypes of type 1
diabetes, the classical acute/rapid-onset form (AT1D) and
slowly progressive insulin-dependent diabetes mellitus
(SPIDDM; now better known as latent autoimmune diabetes
in adults [LADA] [2]), have been classified by a WHO con-
sultation [3] and numerous studies, and diagnostic criteria for
SPIDDMhave been established by the Japan Diabetes Society
(JDS) [4]. In the Campbell-Thompson study [1] the data on
the two type 1 diabetes subtypes were potentially conflated
with the result that data on pancreatic weight became less
specific. We previously reported that the pancreases of
patients with SPIDDM [5, 6] had a high frequency of reduced
pancreas size and characteristic pancreatic ductal changes
(cystic lesions or dilation and narrowing of pancreatic ducts),
both of which are associated with pancreatic weight, while the
pancreases of patients with classical AT1D did not [6].
Second, the Campbell-Thompson paper [1] argued that
pancreases with reduced weight had lobular differences; this
is related to currently disputed issues including lobular atro-
phy and exocrine inflammation in type 1 diabetic donor
pancreases [7, 8]. Campbell-Thompson’s report [1] prompted
us to study not only pancreatic weight but also pancreatic
ductal changes, which are closely related to pancreatic lobular
changes, in autopsied pancreases from individuals with the
two subtypes of type 1 diabetes, SPIDDM and AT1D.
Eleven pancreases from autopsied SPIDDM patients (M/F,
5/6; age, 64±14 years; range, 42–87 years; duration of diabe-
tes, 13±7 years; range, 0.3–24 years), ten pancreases from
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AT1D patients (M/F, 5/5; age, 60 ± 9 years; range,
42–74 years; duration of diabetes, 26 ± 11 years; range,
13–47 years), 15 pancreases from patients with type 2 diabetes
(M/F, 11/4; age, 72±14 years; range, 43–92 years; duration of
diabetes, 13±8 years; range, 3–28 years), and 19 pancreases
from patients without diabetes (M/F, 10/9; age, 66±6 years;
range, 53–82 years) were reviewed. All donors were of Japa-
nese ethnicity. Pancreases from heavy alcohol users and pa-
tients who had a history of DPP-4 inhibitor use and/or pan-
creatic tumours were excluded from the study. All SPIDDM
cases were positive for GAD autoantibodies (mean titre,
56.9 U/ml; range, 3.4–398.0 U/ml; normal, <1.5 U/ml) and
were treated with insulin. Their data met the JDS diagnostic
criteria for SPIDDM [4]. Pancreatic tissue acquisition and data
collection were performed between 1982 and 2014. The
autopsied samples were obtained from Toranomon Hospital
(Tokyo, Japan), University of Yamanashi (Chuo, Japan) and
Saitama Saiseikai Hospital (Saitama, Japan). Tissues from the
pancreatic body and tail were formalin-fixed and
paraffin-embedded. Written informed consent was obtained
from the next of kin on behalf of the autopsied patients. The
institutional review boards of the University of Yamanashi
and Toranomon Hospital approved all study protocols pre-
sented. Fisher’s exact test was used to evaluate the frequencies
of lesions. Comparisons between groups were performed
using the Kruskal–Wallis test and the Mann–Whitney U test.
Values are expressed as mean±SD.
Pancreatic weight in cases of SPIDDM (29.8±8.2 g, range,
18.4–45.0 g, n=11) was significantly lower than in cases of
AT1D (42.1±7.3 g, range, 30.0–59.5 g, n=10, p<0.0059 vs
SPIDDM), type 2 diabetes (66.9 ± 19.4 g, range, 32.0–
100.0 g, n=15, p<0.0001 vs SPIDDM) and non-diabetic
controls (79.3±9.3 g, range, 63.1–95.1 g, n=10, p<0.0002
vs SPIDDM). All SPIDDM pancreases showed extensive
pancreatitis with mononuclear cell infiltration, fibrosis and
lobular atrophy of the exocrine tissues (Fig. 1a). Dilation of
the pancreatic duct, a sign of chronic ductal hyper-pressure,
was also observed in all 11 SPIDDM pancreases (Fig. 1a).
Ductal epithelial hyperplasia/dysplasia (DEHD)—tall, colum-
nar, mucin-rich cells with nuclear atypia (Fig. 1b)—were ob-
served in the branches and smaller ducts in 73% of SPIDDM
pancreases (8/11; 95% CI, 46%, 98%), compared with 10%
(1/10; 95% CI, 0%, 29%; p=0.0007 vs SPIDDM) of AT1D
pancreases, 13% of type 2 diabetes pancreases (2/15; 95% CI,
3%, 34%; p=0.0033 vs SPIDDM) and 5% of non-diabetic
controls (1/19; 95% CI, 0.2%, 28%; p=0.0002 vs SPIDDM).
The pancreatic duct in cases of SPIDDM showed a dilated
lumen filled with mucus and sequestrated contents in all eight
cases with DEHD lesions (Fig. 1a). Two SPIDDM pancreases
that lacked DEHD in the examined pancreatic sections had
mucous contents in dilated pancreatic ducts, suggesting the
presence of downstream pancreatic duct obstruction and up-
stream occult DEHD. One SPIDDM pancreas, which was
found to have a tortuous and dilated main pancreatic duct
and cystic changes in the branched ducts in a previous study
using endoscopic retrograde pancreatography [6] (Fig. 1c),
had DEHD, lobular atrophy and dilated branched ducts with
mucous contents (Fig. 1a, b).
We found that pancreatic weight was significantly lower in
SPIDDM cases than in AT1D cases. A higher frequency of
Fig. 1 (a) Histological features in a pancreas from a patient with
SPIDDM (woman, 76 years of age at autopsy). Marked atrophy of the
exocrine pancreas, dilated pancreatic duct (arrows), pancreatic DEHD
(rectangle) and mucinous contents and cell debris in the pancreatic duct
(arrowhead) are shown. Haematoxylin and eosin (HE) staining, magnifi-
cation ×40, scale bar, 250μm. (b) Magnified view of the DEHD shown in
(a) with nuclear atypia. The ductal lumen is filled with mucinous contents
and cell debris (arrowhead), apparently causing ductal obstruction. HE
staining, magnification ×200, scale bar, 50 μm. (c) Pancreatic ductal
changes shown by an endoscopic retrograde pancreatography in the same
case shown in (a) and (b). A tortuous dilated or narrow main pancreatic
duct (arrows) and cystic changes in the branched ducts (arrowheads) were
identified 7 years before the patient’s death
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DEHD with lobular atrophy was observed in SPIDDM than in
AT1D. Suda et al [9] showed that DEHD occurs at multiple
pancreatic ductal sites with highly viscous mucinous secretions
and epithelial cell debris. These mucinous secretions and
DEHD frequently obstruct the pancreatic branch ducts and in-
duce obstructive chronic pancreatitis in the upstream pancreatic
lobes and lobular atrophy [9]. These characteristic lesions are
likely to be related to the reduced weight of the pancreas in
SPIDDM and are potentially present in a proportion of patients
in Campbell-Thompson’s study [1]. It may be possible that
exocrine inflammation induced by DEHD-induced obstructive
chronic pancreatitis initiates activation of autoreactive Tcells to
islet cells with subsequent destruction of beta cells through a
bystander mechanism [10]. Our data had limitations due to the
small sample size. Further study on the detailed immunological
mechanism(s) of chronic obstructive pancreatitis-induced beta
cell destruction will be needed.
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